|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Preoperative antisepticsin clean/contaminated maxillofacial and oral surgery:prospectiveandomized study显示文摘 | Kosutic D Uglesic V Perkovic D | 2009 | Int J Oral Maxillofac Surg2009，38，2： | 1 |
| 2 | Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo- controlled trial显示文摘 | Neal B Perkovic V de Zeeuw D | 2013 | Am Heart J2013，166，2： | 1 |
| 3 | Corticosteroid Therapy in IgA Nephropathy 显示文摘 | Lv J Xu D Perkovic V | 2012 | Journal of the American Society of Nephrology: JASN2012，23，6： | 1 |
| 4 | Corticosteroid therapy in IgA nephropathy显示文摘 | Lv JC Xu D Perkovic V | 2012 | J Am Soc Nephrol2012，23，6： | 1 |
| 5 | Renal and cardio-protective effects of direct renin inhibition: a systematic literature review显示文摘 | Lambers Heerspink HJ Perkovic V de Zeeuw D | 2009 | J Hypertens2009，27，12： | 1 |
| 6 | Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes显示文摘 | Neal B Perkovic V de Zeeuw D | 2015 | Diabetes Care2015，38，3： | 1 |
| 7 | Is doubling of serum creatinine a valid clinical ' hard' endpoint in clinical nephrology trials 显示文摘 | Lambers Heerspink HJ Perkovic V de Zeeuw D | 2011 | Nephron Clin Pract2011，119，3： | 1 |
| 8 | Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study(CANVAS)--a randomized placebo-controlled trial显示文摘 | Neal B Perkovic V de Zeeuw D et aI | 2013 | Am Heart J2013，166，2： | 1 |
| 9 | Endovascular therapy of renovas- cular hypertension in children : Single center analysis 显示文摘 | Radanovi6 B Caci$ Z Perkov D | 2009 | Eur J Pediatr Surg2009，19，3： | 1 |
| 10 | Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes显示文摘 | Neal B Perkovic V de Zeeuw D | 2015 | Diabetes Care2015，38，： | 1 |
| 11 | Venous spread of renal cell carcinoma:MDCT显示文摘 | Stem Padovan B Perkov D | 2007 | Abdom Imaging2007，32，4： | 1 |
| 12 | Corticosteroid therapy in IgA nephropathy 显示文摘 | Lv J Xu D Perkovic V | 2012 | J Am Soc Nephrol2012，23，6： | 1 |
| 13 | 代盐对临床预后的影响:一项系统综述和荟萃分析显示文摘代盐与脑卒中研究(salt substitute and stroke study, SSaSS)最近报道了富含钾的代盐通过降低血压对心血管结局和死亡的益处。本研究纳入更广泛的研究评估代盐的影响,并量化研究结果的一致性。方法:研究者检索截至2021年8月31日的PubMed、Embase和Cochrane图书馆的资料,纳入报告代盐对血压或临床预后影响的平行组、阶梯楔形或整群随机对照试验。 | Yin X Rodgers A Perkovic A Huang L Li KC Yu J Wu Y Wu JHY Marklund M Huffman MD Miranda JJ Di Tanna GL Labarthe D Elliott P Tian M Neal B 刘青(译) 郑武洪(审校) | 2022 | 中华高血压杂志2022，30，12： | 1 |
| 14 | Corticosteroid therapy in IgA nephropathy显示文摘 | Lv J Xu D Perkovic V | 2012 | J Am Soc Nephrol2012，23，： | 1 |
| 15 | 显示文摘 | Perkovic M W Rillema D P | 1995 | Inog Chem1995，34，： | 1 |
| 16 | HMG CoA reductaseinhibitors (statins) for people with chronic kidney disease not requiringdialysis显示文摘 | Navaneethan S D Pansini F Perkovic V | 2009 | Cochrane Database Syst Rev2009，，00： | 1 |
| 17 | Venous spread of renal cell carcinoma: MDCT显示文摘 | Stern Padovan R Perkov D Smiljanic R | 2007 | Abdom Imaging2007，32，： | 1 |
| 18 | Corticosteroid therapy in lgA ne- phropathy 显示文摘 | LV J XU D PERKOVIC V | 2012 | J Am Soc Nephro12012，23，6： | 1 |
| 19 | Structure, physical and photophysical properties, and charge separation studies of Re (bpm) (CO)3L^n+ complexes (L = CH3CN, py, MeQ^+ , py-PTZ) 显示文摘 | Randy J Shver Marc W Perkovic D Paul Rillema | 1995 | Inog Chem1995，34，： | 1 |
| 20 | Pharmacological intervention410 in renal fibrosis and vascular sclerosis显示文摘 | Becker G J Perkovic V Hewitson T D | 2001 | J Nephrol2001，14，41： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员